Dr. Rebecca Manno of the Johns Hopkins Arthritis Center discusses exercise, joint damage and flares in arthritis patients.
Key Points The Johns Hopkins Arthritis Center conducted a study to determine the presence of gum disease in patients who have Rheumatoid Arthritis (RA). Oral health exams were performed on patients who have RA and healthy volunteers for comparison. Data was collected from 100 RA patients and 40 healthy volunteers. 70% of the RA patients […]
A recent study by the Johns Hopkins Arthritis Center reveals yoga holds positive results for arthritis sufferers in terms of both mind and body.
OTREXUP™ (methotrexate) injection was recently approved by the U.S. Food and Drug Administration.
It is indicated for adults with severe, active rheumatoid arthritis, or children with active polyarticular juvenile idiopathic arthritis who have failed first line therapies. It is also indicated for severe, recalcitrant, disabling psoriasis.
Tofacitinib (Xeljanz®) is the first of a unique class of oral kinase inhibitors to be FDA approved for the treatment of rheumatoid arthritis (RA). Tofacitinib is a selective inhibitor of Janus kinase (JAK) enzymes.